Massimo Giachetti/iStock Editorial via Getty Images AMC Entertainment ( AMC ) may issue and sell up to $150M worth of its Class A common stock. The company entered into a sales and registration agreement with Goldman Sachs, B. Riley Securities, and Yorkville Securities to act as sales agents. The theater chain plans to use proceeds, if any, to strengthen its balance sheet and reinvest in its core ...
Massimo Giachetti/iStock Editorial via Getty Images AMC Entertainment ( AMC ) may issue and sell up to $150M worth of its Class A common stock. The company entered into a sales and registration agreement with Goldman Sachs, B. Riley Securities, and Yorkville Securities to act as sales agents. The theater chain plans to use proceeds, if any, to strengthen its balance sheet and reinvest in its core business to elevate and differentiate the movie-going experience under its AMC GO Plan. AMC shares were down 1.3% premarket. More on AMC AMC Entertainment's On A Short Leash AMC Entertainment: Disappointing Box Office Results Lead To Continued Cash Burn And Dilution (Rating Downgrade) AMC Shareholders Approve Massive Dilution Melania documentary beats box-office forecasts with $7M opening AMC projects wider full-year net loss but turns optimistic about 2026
Novo Nordisk Slaps HIMS With Lawsuit Over Copycat Wegovy Pill As GLP-1 Feud Erupts The GLP-1 feud between Hims & Hers Health and Novo Nordisk keeps accelerating by the day. HIMS rejected again trying to make a criminal racket into a business model https://t.co/URBLu257l8 — zerohedge (@zerohedge) February 6, 2026 The latest is that Novo is now taking legal action against HIMS, alleging that the tel...
Novo Nordisk Slaps HIMS With Lawsuit Over Copycat Wegovy Pill As GLP-1 Feud Erupts The GLP-1 feud between Hims & Hers Health and Novo Nordisk keeps accelerating by the day. HIMS rejected again trying to make a criminal racket into a business model https://t.co/URBLu257l8 — zerohedge (@zerohedge) February 6, 2026 The latest is that Novo is now taking legal action against HIMS, alleging that the telehealth firm " unlawfully mass markets unapproved versions of Novo Nordisk's FDA-approved semaglutide medicines, deceiving patients and putting their health at risk." In late January, Novo released a $149 per month Wegovy pill, with HIMS just days later releasing a GLP-1 copycat pill of Wegovy for $49 a month. By late last week, FDA Commissioner Marty Makary warned against companies "mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products." FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products. The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs. — Dr. Marty Makary (@DrMakaryFDA) February 5, 2026 Then, on Saturday , not even a day after Makary's comments, HIMS pulled the GLP-1 copycat pill ... *HIMS & HERS TO STOP OFFERING WEIGHT LOSS PILL https://t.co/tiQoqBHf0K — zerohedge (@zerohedge) February 7, 2026 Back to Novo's lawsuit. Here are the three takeaways : Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk's FDA-approved semaglutide medicines, deceiving patients and putting their health at risk Novo Nordisk takes decisive legal action to stop Hims' illegal conduct, protect public health, and defend the scientific innovations that deliver better health outcomes to Americans living with serious chronic diseases like obesity and diabetes Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages " Hims & Hers is ma...
JHVEPhoto/iStock Editorial via Getty Images BD ( BDX ), the MedTech firm also known as Becton, Dickinson, traded lower in the premarket on Monday despite posting better-than-expected financials for Q1 fiscal 2026, as its life sciences segment trailed Wall Street estimates. Concurrently, BD ( BDX ) announced the completion of a transaction to combine its Biosciences & Diagnostic Solutions business ...
JHVEPhoto/iStock Editorial via Getty Images BD ( BDX ), the MedTech firm also known as Becton, Dickinson, traded lower in the premarket on Monday despite posting better-than-expected financials for Q1 fiscal 2026, as its life sciences segment trailed Wall Street estimates. Concurrently, BD ( BDX ) announced the completion of a transaction to combine its Biosciences & Diagnostic Solutions business with its rival life sciences company, Waters ( WAT ). BDX added that out of the $4B of cash distribution it is expected to receive from the deal, it would deploy $2B for share buybacks. “With this significant milestone in our strategy to drive shareholder value, we fully pivot to New BD and the next chapter of the company's growth,” said CEO Tom Polen. As for Q1 financials, the company reported $2.91 in adjusted earnings per share on $5.3B in revenue, indicating a ~15% YoY decline and ~2% YoY growth, beating the consensus by $0.10 and $100M, respectively. BD Life Sciences added $766M to the topline with an ~8% YoY contraction compared to $1.3B projected by analysts, according to Bloomberg data. However, BD’s ( BDX ) other segments offset the impact, with BD Interventional and Connected Care generating $1.3B and $1.1B, respectively, each with a ~6% YoY growth. Looking ahead, BDX reaffirmed its full-year outlook for FY26, projecting $12.35 - $12.65 of adjusted EPS on more than a low-single-digit growth on GAAP revenue, compared to $14.79 and ~2% YoY growth in the consensus, respectively. More on Becton, Dickinson Becton, Dickinson And Company: Rightfully Re-Rated (Downgrade) Becton, Dickinson: Our New, Long, Special Situation Investment Becton, Dickinson beats top-line and bottom-line estimates; updates FY26 EPS outlook Becton, Dickinson Q1 2026 Earnings Preview Seeking Alpha’s Quant Rating on Becton, Dickinson
Nordic power prices surged to their highest level since the height of the energy crisis in late 2022 as a severe cold snap boosts demand and low wind levels squeeze supplies. Day-ahead prices prices climbed 6.8% to €158.53 a megawatt-hour on the Nord Pool exchange, based on national rates across the Nordic and Baltic markets. Wind generation across the region is running at roughly one-third of nor...
Nordic power prices surged to their highest level since the height of the energy crisis in late 2022 as a severe cold snap boosts demand and low wind levels squeeze supplies. Day-ahead prices prices climbed 6.8% to €158.53 a megawatt-hour on the Nord Pool exchange, based on national rates across the Nordic and Baltic markets. Wind generation across the region is running at roughly one-third of normal levels, according to a Bloomberg model. Unusually cold weather has gripped the Nordic region since mid-January, according to data from Atmospheric G2, with little sign of relief before late February. Forecasts from the European Centre for Medium-Range Weather Forecasts show the prolonged cold spell is set to persist for at least another week. “With temperatures and precipitation amounts still below average it adds up to a very bullish cocktail,” said Karsten Sander Nielsen, a market analyst at Mind Energy. Temperatures are expected to plunge further this week as a high-pressure system near Greenland funnels frigid Arctic air southward. Average temperatures in Norway, Sweden and Finland may drop as much as 7C to 9C below the seasonal norm, according to MetDesk meteorologist Richard Martin-Barton. Read: Deep Freeze Ices Finland Wind Turbines, Sending Output Plunging The same weather pattern is also suppressing wind speeds, creating calm conditions across the region. As a result, wind power generation could run as much as 20% below normal, MetDesk said. Output on Tuesday is forecast at about 3.4 gigawatts, according to Bloomberg’s model. Meanwhile, the French day-ahead contract fell to €55.56, its lowest level since Jan. 1, on mild temperatures and strong nuclear generation.
In a final that demonstrated the strength of women's freestyle skiing, Mathilde Gremaud successfully defended her Olympic title by only 0.38 points. China's Eileen Gu - arguably a bigger star off the slopes - took silver, but crashed on her final run to allow Gremaud a victory lap, a Switzerland flag tied around her neck, billowing in the wind as she soaked up her moment on the course. Muir is one...
In a final that demonstrated the strength of women's freestyle skiing, Mathilde Gremaud successfully defended her Olympic title by only 0.38 points. China's Eileen Gu - arguably a bigger star off the slopes - took silver, but crashed on her final run to allow Gremaud a victory lap, a Switzerland flag tied around her neck, billowing in the wind as she soaked up her moment on the course. Muir is one of Team GB's best medal hopes at the Milan-Cortina Games, and has another shot at the podium when she competes in the big air starting on Saturday. Four years ago in Beijing, Scotland's Muir was GB's youngest competitor at 17, but she finished fifth in the big air and eighth in the slopestyle. After Beijing Muir achieved three World Cup podiums, but in December 2023 an MRI scan showed she had been competing with a fully torn anterior cruciate ligament (ACL). An operation followed in early 2024, as well as surgery on a shoulder problem that had troubled her for some time. Eleven months later she was back on snow, and her maiden World Cup gold arrived in Tignes in March 2025. Two more have followed this season, as well as slopestyle gold and big air silver at the invitation-only X Games on the eve of the Olympics. "I'm going to look forward to big air, but I just need to take this one in," Muir said. "I got to see my famly. They were hugging me a bit too tightly - I was getting a bit claustrophobic. They're proud of me no matter what, so I can take that away."
Italian prosecutors have placed Delivery Hero SE ’s Italian food-delivery unit under judicial control as part of a criminal investigation into alleged labor exploitation. The measure provides for a court-appointed administrator to oversee the operations of Milan-based Foodinho Srl, the Italian operator of Glovo’s delivery business, according to a court order seen by Bloomberg News. Delivery Hero a...
Italian prosecutors have placed Delivery Hero SE ’s Italian food-delivery unit under judicial control as part of a criminal investigation into alleged labor exploitation. The measure provides for a court-appointed administrator to oversee the operations of Milan-based Foodinho Srl, the Italian operator of Glovo’s delivery business, according to a court order seen by Bloomberg News. Delivery Hero agreed to acquire a majority stake in Spanish startup Glovo at the end of 2021 . Prosecutors said the step was taken to halt what it’s described as an urgent and ongoing condition of labor exploitation. Delivery Hero shares plunged as much as 6.6% after the news . “Delivery Hero and its brands always collaborate with judicial authorities across all the jurisdictions where we operate,” a spokesperson for the company said. The move highlights intensifying scrutiny of Italy’s gig-economy sector and broader labor practices, and comes after several probes into employers in luxury sectors. Prosecutors and labor authorities have increasingly focused on pay, working conditions and the use of digital platforms to manage workers, with Milan prosecutors in particular pursuing judicial oversight as a way to address alleged abuses. In Italy judicial control allows a company to keep operating while under court supervision. Judges appoint administrators to oversee management and ensure compliance, often to stop alleged labor abuses while protecting jobs. Delivery Hero is one of the biggest providers of app-based food and grocery delivery in Italy, with bicycles and e-bikes common in city centers. The alleged misconduct affected about 40,000 riders across the country, court document says. According to the prosecutors, riders were paid compensation deemed disproportionate to the quantity and quality of work performed, and in breach of collective labor rules. Many riders earned incomes below the poverty threshold despite working long hours. Read More: LVMH’s Loro Piana Faces Court Oversight i...
Shares could lose more than a third of their value Monday following the disclosure of an accounting investigation and a big reset of the company’s financial guidance.
Shares could lose more than a third of their value Monday following the disclosure of an accounting investigation and a big reset of the company’s financial guidance.
Source: CNBC ORCL $ 142.82 + Infinity % 1D 1D 5D 1M 3M 6M YTD 1Y 5Y 1D Line Candle Analyst Views on ORCL Wall Street analysts forecast ORCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORCL is 309.59 USD with a low forecast of 180.00 USD and a high forecast of 400.00 USD. However, analyst price targets are subjective and often ...
Source: CNBC ORCL $ 142.82 + Infinity % 1D 1D 5D 1M 3M 6M YTD 1Y 5Y 1D Line Candle Analyst Views on ORCL Wall Street analysts forecast ORCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORCL is 309.59 USD with a low forecast of 180.00 USD and a high forecast of 400.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals. 34 Analyst Rating Wall Street analysts forecast ORCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORCL is 309.59 USD with a low forecast of 180.00 USD and a high forecast of 400.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals. 25 Buy 9 Hold 0 Sell Moderate Buy Current: 136.480 Low 180.00 Averages 309.59 High 400.00 Current: 136.480 Low 180.00 Averages 309.59 High 400.00 DA Davidson Neutral -> Buy upgrade $180 2026-02-09 New Reason DA Davidson Price Target $180 AI Analysis 2026-02-09 New upgrade Neutral -> Buy Reason DA Davidson upgraded Oracle (ORCL) to Buy from Neutral with an $180 price target. The firm believes that a revamped OpenAI will return to its position as Google's (GOOGL) top challenger and with a fresh stack of capital be able to live up to its obligations this year, including to Oracle, which it sees removing the biggest concern from Oracle, the analyst tells investors. Bernstein Outperform to NULL downgrade $339 -> $313 2026-02-09 New Reason Bernstein Price Target $339 -> $313 2026-02-09 New downgrade Outperform to NULL Reason Bernstein lowered the firm's price target on Oracle to $313 from $339 and keeps an Outperform rating on the shares. The firm says one of the major overhangs o...
shaunl/E+ via Getty Images Valaris ( VAL ) +15.7% pre-market Monday after Transocean ( RIG ) agreed to acquire the company in an all-stock deal valued at ~$5.8B, creating an offshore drilling industry leader with a fleet of 73 rigs, including 33 ultra-deepwater drillships, nine semisubmersibles and 31 modern jackups. Under the deal terms, Valaris ( VAL ) shareholders will receive a fixed exchange ...
shaunl/E+ via Getty Images Valaris ( VAL ) +15.7% pre-market Monday after Transocean ( RIG ) agreed to acquire the company in an all-stock deal valued at ~$5.8B, creating an offshore drilling industry leader with a fleet of 73 rigs, including 33 ultra-deepwater drillships, nine semisubmersibles and 31 modern jackups. Under the deal terms, Valaris ( VAL ) shareholders will receive a fixed exchange ratio of 15.235 common shares of Transocean ( RIG ) stock for each Valaris common share; upon completion and on a fully diluted basis, Transocean shareholders will own ~53% of the combined company, with Valaris shareholders owning the remaining 47%. Based on the most recent closing stock prices, the transaction implies a combined enterprise value of ~$17B. Transocean ( RIG ) said the acquisition will unlock more than $200M in identified cost synergies, in addition to its ongoing cost-reduction program which is expected to reduce costs by more than $250M total through 2026. Transocean's ( RIG ) senior management team will be led by CEO Keelan Adamson , and Jeremy Thigpen will serve as Executive Chairman; the board will be comprised of nine current Transocean directors and two current Valaris ( VAL ) directors. More on Transocean and Valaris Transocean: The Mightiest Machines Transocean's Surge Doesn't Mean Buy Just Yet Valaris: Stormy Oil Markets Shift My High Conviction Here
Key Points Working another year could eliminate a zero-income year from your benefit calculation. If you're earning more now than in the past, working longer could boost your average indexed monthly earnings, a key determinant for benefits. It could also enable you to delay Social Security until you're eligible for larger checks. The $23,760 Social Security bonus most retirees completely overlook ...
Key Points Working another year could eliminate a zero-income year from your benefit calculation. If you're earning more now than in the past, working longer could boost your average indexed monthly earnings, a key determinant for benefits. It could also enable you to delay Social Security until you're eligible for larger checks. The $23,760 Social Security bonus most retirees completely overlook › After working for several decades, the idea of stepping back and claiming Social Security sounds pretty good. As long as you're at least 62 and have worked long enough to qualify for retirement benefits, there's nothing to stop you from applying. However, it's possible that signing up as soon as you can could shortchange you in ways you might not expect. Here are three ways working one extra year could lead to larger Social Security checks for the rest of your life. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » 1. You could eliminate a zero-income year from your benefit calculation The Social Security benefit formula considers your average monthly income from your 35 highest-earning years, adjusted for inflation. This is known as your average indexed monthly earnings (AIME). You can claim checks with a work history as short as 10 years. But if you do this, you'll have zero-income years factored into your benefit calculation. Even one of these can permanently reduce your checks. If you earned $60,000, adjusted for inflation, for 35 straight years, you would be eligible for a monthly benefit of about $2,346 at your full retirement age (FRA). If you only had a 34-year work history, that benefit would drop to $2,300 per month -- a $46 difference. Working one more year would help you eliminate this zero-income year from your benefit calculation, resulting in permanently larger checks. 2. Working longer than 35 years could still boost your AIME Many people...